Literature DB >> 25502838

Host miR155 promotes tumor growth through a myeloid-derived suppressor cell-dependent mechanism.

Siqi Chen1, Long Wang2, Jie Fan1, Cong Ye1, Donye Dominguez1, Yi Zhang3, Tyler J Curiel2, Deyu Fang4, Timothy M Kuzel1, Bin Zhang5.   

Abstract

miR155 is a regulator of immune cell development and function that is generally thought to be immunostimulatory. However, we report here that genetic ablation of miR155 renders mice resistant to chemical carcinogenesis and the growth of several transplanted tumors, suggesting that miR155 functions in immunosuppression and tumor promotion. Host miR155 deficiency promoted overall antitumor immunity despite the finding of defective responses of miR155-deficient dendritic cells and antitumor T cells. Further analysis of immune cell compartments revealed that miR155 regulated the accumulation of functional myeloid-derived suppressive cells (MDSC) in the tumor microenvironment. Specifically, miR155 mediated MDSC suppressor activity through at least two mechanisms, including SOCS1 repression and a reduced ability to license the generation of CD4(+)Foxp3(+) regulatory T cells. Importantly, we demonstrated that miR155 expression was required for MDSC to facilitate tumor growth. Thus, our results revealed a contextual function for miR155 in antitumor immunity, with a role in MDSC support that appears to dominate in tumor-bearing hosts. Overall, the balance of these cellular effects appears to be a root determinant of whether miR155 promotes or inhibits tumor growth. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25502838      PMCID: PMC4315710          DOI: 10.1158/0008-5472.CAN-14-2331

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  64 in total

Review 1.  MicroRNAs: small RNAs with a big role in gene regulation.

Authors:  Lin He; Gregory J Hannon
Journal:  Nat Rev Genet       Date:  2004-07       Impact factor: 53.242

2.  MicroRNA-155 regulates inflammatory cytokine production in tumor-associated macrophages via targeting C/EBPbeta.

Authors:  Min He; Zhenqun Xu; Tong Ding; Dong-Ming Kuang; Limin Zheng
Journal:  Cell Mol Immunol       Date:  2009-10       Impact factor: 11.530

3.  Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer.

Authors:  Ping-Ying Pan; Ge Ma; Kaare J Weber; Junko Ozao-Choy; George Wang; Bingjiao Yin; Celia M Divino; Shu-Hsia Chen
Journal:  Cancer Res       Date:  2009-12-08       Impact factor: 12.701

4.  Antigen-specific immunity and cross-priming by epithelial ovarian carcinoma-induced CD11b(+)Gr-1(+) cells.

Authors:  Kei Tomihara; Miao Guo; Takako Shin; Xiuhua Sun; Sara M Ludwig; Michael J Brumlik; Bin Zhang; Tyler J Curiel; Tahiro Shin
Journal:  J Immunol       Date:  2010-04-28       Impact factor: 5.422

5.  Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer.

Authors:  Esmerina Tili; Jean-Jacques Michaille; Dorothee Wernicke; Hansjuerg Alder; Stefan Costinean; Stefano Volinia; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-07       Impact factor: 11.205

Review 6.  Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy?

Authors:  A W Tong; J Nemunaitis
Journal:  Cancer Gene Ther       Date:  2008-03-28       Impact factor: 5.987

7.  IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers.

Authors:  Bin Zhang; Theodore Karrison; Donald A Rowley; Hans Schreiber
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

8.  Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice.

Authors:  Maciej Kujawski; Marcin Kortylewski; Heehyoung Lee; Andreas Herrmann; Heidi Kay; Hua Yu
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

9.  The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies.

Authors:  Mariangela De Robertis; Emanuela Massi; Maria Luana Poeta; Simone Carotti; Sergio Morini; Loredana Cecchetelli; Emanuela Signori; Vito Michele Fazio
Journal:  J Carcinog       Date:  2011-03-24

10.  microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells.

Authors:  Elena Vigorito; Kerry L Perks; Cei Abreu-Goodger; Sam Bunting; Zou Xiang; Susan Kohlhaas; Partha P Das; Eric A Miska; Antony Rodriguez; Allan Bradley; Kenneth G C Smith; Cristina Rada; Anton J Enright; Kai-Michael Toellner; Ian C M Maclennan; Martin Turner
Journal:  Immunity       Date:  2007-12-06       Impact factor: 31.745

View more
  52 in total

1.  Regulating Tumor Myeloid-Derived Suppressor Cells by MicroRNAs.

Authors:  Siqi Chen; Yi Zhang; Timothy M Kuzel; Bin Zhang
Journal:  Cancer Cell Microenviron       Date:  2015

Review 2.  Negative Regulation of Cytokine Signaling in Immunity.

Authors:  Akihiko Yoshimura; Minako Ito; Shunsuke Chikuma; Takashi Akanuma; Hiroko Nakatsukasa
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-07-02       Impact factor: 10.005

3.  Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma.

Authors:  Veronica Huber; Viviana Vallacchi; Viktor Fleming; Xiaoying Hu; Agata Cova; Matteo Dugo; Eriomina Shahaj; Roberta Sulsenti; Elisabetta Vergani; Paola Filipazzi; Angela De Laurentiis; Luca Lalli; Lorenza Di Guardo; Roberto Patuzzo; Barbara Vergani; Elena Casiraghi; Mara Cossa; Ambra Gualeni; Valentina Bollati; Flavio Arienti; Filippo De Braud; Luigi Mariani; Antonello Villa; Peter Altevogt; Viktor Umansky; Monica Rodolfo; Licia Rivoltini
Journal:  J Clin Invest       Date:  2018-11-05       Impact factor: 14.808

4.  Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.

Authors:  Thomas B Huffaker; Soh-Hyun Lee; William W Tang; Jared A Wallace; Margaret Alexander; Marah C Runtsch; Dane K Larsen; Jacob Thompson; Andrew G Ramstead; Warren P Voth; Ruozhen Hu; June L Round; Matthew A Williams; Ryan M O'Connell
Journal:  J Biol Chem       Date:  2017-09-14       Impact factor: 5.157

5.  OX40+ plasmacytoid dendritic cells in the tumor microenvironment promote antitumor immunity.

Authors:  Kate Poropatich; Donye Dominguez; Wen-Ching Chan; Jorge Andrade; Yuanyuan Zha; Brian Wray; Jason Miska; Lei Qin; Lisa Cole; Sydney Coates; Urjeet Patel; Sandeep Samant; Bin Zhang
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

6.  Avoiding phagocytosis-related artifact in myeloid derived suppressor cell T-lymphocyte suppression assays.

Authors:  Ruth J Davis; Christopher Silvin; Clint T Allen
Journal:  J Immunol Methods       Date:  2016-11-14       Impact factor: 2.303

7.  Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer.

Authors:  Donye Dominguez; Cong Ye; Zhe Geng; Siqi Chen; Jie Fan; Lei Qin; Alan Long; Long Wang; Zhuoli Zhang; Yi Zhang; Deyu Fang; Timothy M Kuzel; Bin Zhang
Journal:  J Immunol       Date:  2016-12-23       Impact factor: 5.422

Review 8.  MicroRNA heterogeneity in melanoma progression.

Authors:  Anita Thyagarajan; Kenneth Y Tsai; Ravi P Sahu
Journal:  Semin Cancer Biol       Date:  2019-06-01       Impact factor: 15.707

9.  MicroRNA-155 deletion promotes tumorigenesis in the azoxymethane-dextran sulfate sodium model of colon cancer.

Authors:  Kandy T Velázquez; Reilly T Enos; Jamie L McClellan; Taryn L Cranford; Ioulia Chatzistamou; Udai P Singh; Mitzi Nagarkatti; Prakash S Nagarkatti; Daping Fan; E Angela Murphy
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-01-07       Impact factor: 4.052

10.  Targeting Ornithine Decarboxylase by α-Difluoromethylornithine Inhibits Tumor Growth by Impairing Myeloid-Derived Suppressor Cells.

Authors:  Cong Ye; Zhe Geng; Donye Dominguez; Siqi Chen; Jie Fan; Lei Qin; Alan Long; Yi Zhang; Timothy M Kuzel; Bin Zhang
Journal:  J Immunol       Date:  2015-12-09       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.